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Abstract: Immunohistochemical loss of the succinate dehydrogenase subunit B (SDHB) 
has recently been reported as a surrogate biomarker of malignancy in sporadic and familial 
pheocromocytomas and paragangliomas through the activation of hypoxia pathways. 
However, data on the prevalence and the clinical implications of SDHB immunoreactivity 
in ileal neuroendocrine tumors are still lacking. Thirty-one consecutive, advanced primary 
midgut neuroendocrine tumors and related lymph node or liver metastases from 24 males 
and seven females were immunohistochemically assessed for SDHB. All patients were G1 
tumors (Ki-67 labeling index ≤2%). SDHB immunohistochemistry results were expressed 
as immunostaining intensity and scored as low or strong according to the internal control 
represented by normal intestinal cells. Strong positivity for SDHB, with granular cytoplasmatic 
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reactivity, was found in 77% of primary tumors (T), whilst low SDHB expression was 
detected in 90% of metastases (M). The combined analysis (T+M) confirmed the loss of 
SDHB expression in 82% of metastases compared to 18% of primary tumors. SDHB 
expression was inversely correlated with Ki-67 labeling index, which accounted for 1.54% 
in metastastic sites and 0.7% in primary tumors. A correlation between SDHB expression 
loss, increased Ki-67 labeling index and biological aggressiveness was shown in advanced 
midgut neuroendocrine tumors, suggesting a role of tumor suppressor gene. 
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1. Introduction 
Ileal neuroendocrine tumors (INETs) are the most common type of neuroendocrine neoplasms in 
the gastrointestinal tract, with a male prevalence and a median age at the time of diagnosis of 66 years. 
They are mainly composed of enterochromaffin cells (EC) producing serotonin and substance P [1,2]. 
A distinctive feature of INETs, especially when involving the liver, is their capability of causing 
distinct clinical syndromes [1,3,4], which can be faithfully monitored measuring the relevant hormones 
in the bloodstream. Surgical resection can be curative in early stage patients [5,6], but most of them 
present with liver involvement at the time of diagnosis, so tumor grading and staging according to 
WHO/AJCC/ENET criteria are likely to play the most important role in the prognostic and therapeutic 
assessment of INETs [6]. Accordingly, neuroendocrine carcinomas, which show high proliferative 
activity as reflected by Ki67 labeling index (LI) over 20%, are treated with cisplatin-etoposide 
combination chemotherapy similarly to small cell lung cancer (SCLC) [7,8], whereas most ileal 
neuroendocrine tumors are slowly growing neoplasms, which mainly depend on angiogenesis for their 
maintenance and growth [9–14]. Hence the search for new markers capable of getting new insights 
into the biological properties of INETs may be clinically warranted. 
The succinate dehydrogenase (SDH) enzyme (also known as succinate ubiquinone oxydoreductase) 
is a highly conserved heterotetrameric protein, with SDHA and SDHB functioning as catalytic 
subunits, which protrudes into the mitochondrial matrix and is anchored to the inner membrane by 
means of SDHC and SDHD subunits, the latter also providing the binding site for ubiquinone [15–40]. 
SDHB is normally ubiquitously expressed with granular cytoplasmic immunostaining reflecting its 
mitochondrial location [41,42]. It is also been shown that silencing SDHB expression induces tumor-like 
phenotypic traits in cell cultures [43], and that the loss of any subunit protein, especially B, leads to the 
loss of SDH expression due to destabilization of its complex [20,44]. However, data on the prevalence 
of SDHB in INETs and its implications on tumor differentiation and prognosis are still lacking, to the 
best of our knowledge. 
This study was aimed at evaluating the distribution of SDHB by immunohistochemistry (IHC) in  
31 INETs and corresponding lymph node or liver metastases in order to explore its diagnostic and 
prognostic implications. 
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2. Results and Discussion 
There were no differences between functioning (FT) and nonfunctioning (NFT) groups in age, 
gender, clinical outcome and medical treatment. The only significant association was the greater liver 
tumor load (p = 0.0000026) and the increased basal chromogranin A (CgA) serum level (p = 0.0113) 
in the NFT group (Table 1). 
Table 1. Demographic and clinicopathologic information on the 31 INETs patients  
under evaluation. 
Variable NFT FT p Value 
Age (Years) 
<50 8 4 0.106 
51–70 7 9  
>70 0 3  
Gender 
Male 13 12 0.653 
Female 2 4  
Outcome 
DOD 5 8  
AW 0 0 0.3480 
AWD 7 3  
A.NED 3 3  
Medical 
Treatment 
SMS 12 13  
CT 2 3 0.653 
SMS+CT 0 0  
NO 1 0  
Liver Tumor Load 
H1 13 1 0.0000026 
H2 1 1  
H3 1 14  
Basal CgA ng/mL 
<200 10 3 0.0113 
>200 5 13  
F, female; M, male; DOD, died of disease; AW, alive and well; AWD, alive with disease; A.NED, 
not evidence of disease; H1, liver involvement <25%; H2, liver involvement between 25 and 50%; 
H3, liver involvement >50%; INETs, ileal neuroendocrine tumors; SMS, somatostatin analogues; 
CT, chemotheraphy; CgA, chromogranin A. 
SDHB immunoreactivity was found in tumor cells of all cases under assessment, but there was a 
significant relationship between SDHB intensity and percentage of immunoreactive cells (test for 
trend) (Table 2). Representative pictures of SDHB and Ki-67 antigen immunoreactivity are depicted in 
Figure 1. In particular, the more the intensity of immunoreactivity, the more the percentage of positive 
cells. The percentage of tumor cells was associated significantly with the site of tumors and Ki67 LI, 
since primary lesions bearing a proliferative activity ≤1.3% showed over 50% SDHB immunoreactive 
tumor cells (Table 3). Likewise, significant associations were found between the site of tumors  
(p < 0.0001) or Ki-67 LI (p < 0.0001) and SDHB immunostaining intensity (Table 3). No significant 
associations were found with age, gender, type of therapy, presence of clinical syndrome, and  
CgA level. 
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Table 2. Relationship between SDH intensity and percentage of positive tumor cells 
 
All Measures 
SDHB intensity 
p Value 
 1 2 3 
All measures 39 19 9 11  
SDHB expression      
1–25% 5 4 0 1  
26–50% 9 6 2 1  
51–75% 15 8 4 3 0.076 (Fisher exact) 
76–100% 10 1 3 6 0.007 (trend) 
Table 3. Distribution of tumor site (primary vs. metastasis) and Ki-67 labeling index according 
to SDHB expression (percentage of positive tumor cells) and immunstaining intensity. 
SDHB 
Expression 
SITE Ki-67 labeling index  
Primary 
Tumor 
Metastases p Value ≤1.3% ≥1.3% p Value 
1–25% 2 3  1 4  
26–50% 2 7 0.013 (trend) 3 6 0.038 
51–75% 7 8  8 7  
76–100% 9 1  7 3  
SDHB Intensity       
1+ 1 18  2 17  
2+ 8 1 <0.0001(trend) 7 2 <0.0001(trend) 
3+ 11 0  10 1  
Ki-67 labeling index: 1.3% represented the median value and was chosen as cut-off for 
distinguishing slower from faster growing tumors within the G1 category. 
Figure 1. Representative pictures of primary neuroendocrine tumors of the ileum stained 
with hematoxylin and eosin (a,d,g), and SDHB (b,e,h) and Ki-67 antigen (c,f,i) 
immunohistochemistry are shown in primary lesions (a–c), and lymph node (d–f) or liver 
metastases (g–i). All tumor cells exhibited granular staining due to the mitochondrial 
accumulation of immunreaction product. A clear gradient of SDHB expression loss can be 
easily appreciated going from primary tumors (panel “b”) to lymph node (panel “e”) and 
liver (panel “h”) metastases. The normal epithelial and mesenchimal cells present in the 
tumor tissue samples served as internal positive controls (for example, the intestinal gland 
structures detectable on the right side of the panel “b” show a clear and specific decoration 
for the marker under assessment). 
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Figure 1. Cont. 
 
Survival analysis showed that the SDHB intensity but not the SDHB percentage of tumors cells 
impacted inversely on the patients’ prognosis, with marginal poorer prognosis being observed in 
individuals loosing SDHB immunoreactivity when considered as a whole (p = 0.1106) and significant 
shorter survival in the subset of metastatic diseases (p = 0.0387) (Figure 2). Other variables correlating 
with reduced survival included the lack of transplant treatment (p = 0.0094) and CgA levels >200  
(p = 0.001). Although proliferative activity by means of Ki-67 labeling index was not a prognostic 
factor in this subset of patients, it was however marginally related to survival in metastases rather than 
primary tumors (p = 0.086). Multivariate analysis according to Cox’s model let emerge CgA level but 
not SDHB immunostaining intensity as an independent factor of survival (Table 4). 
Table 4. Multivariate analysis in 31 nontransplanted patients. 
 HR (95% CI) p Value 
CgA level   
<200 1.00  
>201 8.22 (1.02–66.4) 0.048 
SHDB intensity   
1 1.00  
2–3 1.38 (0.49–3.91) 0.55 
Interesting findings of our study were that SDHB expression correlated with the tumor cell 
differentiation and malignant potential of G1 INETs, and that the percentage of immunoreactive cells 
was associated with the staining intensity (Table 2). As a matter of fact the higher was the loss of 
SDHB immunoreactivity, the higher the proliferative activity (Table 3), the higher the likelihood of 
facing with metastatic sites (Table 3), and the shorter the survival (Figure 2a,b). Accordingly, SDHB 
was likely to behave as tumor suppressor gene in this category of neuroendocrine tumors, in that the 
lack of this protein was associated with parameters of clinical aggressiveness in metastatic tumors and 
reduced life expectation. 
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Figure 2. (A) SDHB immunostining intensity in primary tumors; (B) SDHB 
immunostining intensity in metastatic sites. 
 
(A) 
 
(B) 
Although the switch from respiration to glycolysis in tumor cells has often been considered a 
consequence rather than a cause of cancer [45,46], the discovery that germline, inherited mutations in the 
genes encoding SDH enzyme subunits may cause paragangliomas and phaeochromocytomas [17,19,45–47], 
whether hereditary or sporadic, has however revolutionized this assumption [45,46]. Interestingly, all 
SDH subunits have no cytosolic counterpart unlike most Krebs cycle enzymes, but are imported into 
the mitochondria where they are modified, folded and assembled. Hence, they are able to deeply affect 
the capability of producing energy, whenever these subunits are downregulated in their expression. In 
our investigation, we observed that metastatic sites showed loss of SDHB expression along with a 
higher Ki-67 LI thereby supporting the contention that the development of anaerobic metabolism 
mechanisms could favor an increase of clinical aggressiveness. 
In our paper, we provide evidence for the first time that the assessment of SDHB immunoreactivity 
in well-differentiated INETs may identify a subset of tumors characterized by reduced life expectation, 
which are worth treating more aggressively with multimodality therapy. Moreover, this paper 
challenges the common credence that G1 neuroendocrine tumors of the ileum are uniformly poorly 
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aggressive tumors, while they are likely to be a heterogeneous tumor group harboring different lesions 
with different degrees of malignancy. The loss of function of SDHB as indicated by its relevant  
down-expression might be responsible for a pseudo-hypoxic drive via succinate-induced glycolysis 
and HIF stabilization in normoxic conditions [48], so favoring angiogenesis, tumor growth and 
progression of malignancy [48]. Recent evidences have corroborated the notion of a possible role for 
succinate accumulation due to SDHB activity loss also in epigenetic changes of chromatin via the 
histone H3 methylation in succinate-accumulating tumor cells [48]. Further investigation dealing with 
somatic mutation analysis of SDHB gene is currently in progress in our laboratory to better clarify 
additional molecular mechanisms underlying the loss of SDHB expression in this subset of  
INETs patients. 
3. Experimental Section 
3.1. Patients 
Ileal neuroendocrine tumors from 31 patients (78% males and 22% females, median age 55.5 years, 
range 19 to 75 years) were retrieved from the archives of the Pathology Department of the National 
Cancer Institute of Milan. These cases had been surgically treated from 1992 to 2007 at the 
Department of Surgery of the same Institution. All INETs were G1 neuroendocrine tumors according 
to WHO/AJCC/ENET criterio for tumor grading (Ki-67 labeling index ≤2%). According to clinical 
and laboratory findings, two tumor groups were identified: FT group was defined by the occurrence of 
a compatible clinical syndrome associated with serum elevation and immunohistochemical detection 
of the relevant hormones, and NFT group by the absence of both clinical symptoms and serum 
elevation of hormones, regardless of the presence of immunostaining for any hormones [49–59]. All 
cases were subjected to serum and immunohistochemical assessment for CgA, synapthophisin, 
serotonin, and somatostatin receptor type 2A. Most of patients underwent surgical primary resection 
and all of them presented with distant synchronous liver metastases treated with nodule excision in  
25 patients and liver transplant in 6 patients according to the so-called Milan criteria [60]. In the 
patients undergoing liver transplant, three clinical subgroups were considered according to the amount 
of liver involvement as assessed by surgical staging or CT scan: tumor load <25% (H1), between 25% 
and 50% (H2), and over 50% (H3) [61]. Clinicopathological data on the INETs under evaluation are 
shown in Table 1. 
3.2. Tumors Specimens, Immunohistochemical Methods and Scoring of Data 
The diagnosis of INETs was established by means of the last WHO classification [49,62]. All 
surgical samples (19 primary tumors, 19 metastases and 11 combined primary and metastatic lesions) 
had been fixed in 10% buffered formaldehyde solution and embedded in paraffin. To minimize the 
intratumoral variability because of sampling process, the entire tumor was immunostained if the lesion 
was up to 2 cm in diameter or at least two representative tissue blocks were immnnostained if the 
lesion was larger than 2 cm in diameter. Four μm-thick paraffin sections were reacted with monoclonal 
antibodies against CgA, synaptophysin, serotonin, Ki-67 antigen and SDHB [49] and processed 
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according to previously refined immunohistochemical methods. Internal and external controls were 
used for all markers as appropriate. 
In order to minimize variability in the slide assessment when trying punctual percentages, 
immunohistochemistry results for SDHB were rendered semiquantitatively on a scale from 1+ to 4+, 
taking into account a granular labeling product in the cytoplasm. One-plus tumors showed 
immunoreactivity in up to 25% neoplastic cells, 2+ cases in 26–50% neoplastic cells, 3+ cases in 51–75% 
neoplastic cells, 4+ cases in 76–100% neoplastic cells. Moreover, the immunostaining intensity was 
indicated as low (1+), if fainter than that seen in internal controls, or strong (3+), if more intense than 
the normal internal controls that was in turn indicated as being 2+. As SDHB is ubiquitous in normal cells, 
internal controls included any type of non-neoplastic cells, whether epithelial or mesenchymal. 
3.3. Statistical Analysis 
Associations of categorical variables were evaluated by Fisher’s exact t-test, test for trend or  
chi-square test. Survival estimates were calculated with Kaplan-Maier’s method and compared by 
Cox-Mantel’s log rank test. The comparative importance of explanatory variables on survival time was 
evaluated by means of Cox’s proportional hazard regression model. All the analyses were performed 
using the SAS statistical software (SAS Institute, Inc., Cary, NC, USA). All p-values were based on 
two-sided testing. 
4. Conclusions 
Our study provides the first evidence of a down-regulation of SDHB in well-differentiated INETs 
as likely mechanism contributing to the development of a subset of biologically more aggressive 
tumors as heralded by increased proliferative activity and reduced survival. Further investigation is 
currently in progress in our laboratory on a larger cohort of INETs patients, as well as in other types of 
neuroendocrine tumors, in order to confirm and expand these preliminary data. 
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